Chargement en cours...
Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature
BACKGROUND: Nivolumab is an immune checkpoint inhibitor targeting programmed death-1 protein and has been approved for the treatment of multiple advanced malignancies. Adverse effects of immune checkpoint inhibitors are distinct from conventional cytotoxic chemotherapy and can be life-threatening if...
Enregistré dans:
| Publié dans: | Exp Hematol Oncol |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5941729/ https://ncbi.nlm.nih.gov/pubmed/29761026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-018-0104-y |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|